Sepsis during paediatric leukaemia therapy linked to long-term neurocognitive dysfunction
Severe sepsis during treatment for childhood leukaemia may be associated with an increased risk of moderate-to-severe neurocognitive dysfunction in adulthood, US Study findings indicate.
EV-302 results ‘a leap forward’ for advanced urothelial carcinoma
Phase 3 trial findings demonstrate a significant improvement in overall survival for patients with treatment-naïve, advanced urothelial carcinoma who receive a combination of enfortumab vedotin and pembrolizumab compared with chemotherapy.
FOXO1 fusion status aids paediatric local rhabdomyosarcoma risk assessment
Considering FOXO1 fusion status improves the risk assessment of children with localised rhabdomyosarcoma, suggest study findings published in Cancer.
Tixagevimab plus cilgavimab offers COVID-19 protection for haematological cancer patients
Tixagevimab and cilgavimab immunoprophylaxis may help protect patients with haematological malignancies from COVID-19 infection and hospitalisation, suggests a research letter published in JAMA Oncology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Bevacizumab addition to temozolomide chemotherapy may improve neuroblastoma response
Findings from the BEACON-Neuroblastoma trial suggest that adding bevacizumab to temozolomide-based chemotherapy may improve the objective response rate for children with high-risk, relapsed or refractory disease.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
VTE rates not significantly reduced by apixaban in paediatric ALL or lymphoma
Apixaban does not significantly reduce the rate of venous thromboembolism relative to standard care in paediatric patients with acute lymphoblastic leukaemia or lymphoma, show data from the phase 3 PREVAPIX-ALL trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Intestinal mucositis flags bloodstream infections in feverish children with leukaemia
Monitoring biomarkers of intestinal mucositis in children undergoing treatment for acute leukaemia who develop fever may identify those at risk for bloodstream infections (BSIs), Danish researchers have found.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Upfront dabrafenib plus trametinib supported for paediatric low-grade glioma
First-line treatment with dabrafenib plus trametinib is significantly more likely to achieve a response than chemotherapy for children with low-grade glioma carrying a BRAF V600 alteration, indicates a phase 2 trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Mezigdomide plus dexamethasone show ‘preliminary efficacy’ for refractory multiple myeloma
Phase 1–2 trial findings indicate that the cereblon E3 ubiquitin ligase modulator mezigdomide, given in combination with dexamethasone, could offer a novel oral regimen for patients with heavily pretreated multiple myeloma.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Second primary malignancy risk after lymphoma chemotherapy and HSCT determined
Danish researchers have quantified the risk of second primary malignancy in patients with lymphoma who are treated with high-dose chemotherapy and autologous haematopoietic stem-cell transplantation.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
